Advanced Biomedical Research

Methylation pattern of ALX4 gene promoter as a potential biomarker for blood-based early detection of colorectal cancer

Authors

Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: To develop a non-invasive screening method for colorectal cancer, we evaluated the methylation of ALX4 gene promoter in serum samples from patients with colorectal cancer (CRC) and equal number of healthy individuals.
Materials and Methods: In serum samples from 25 patients with colorectal cancer and 25 healthy control subjects, isolated serum free-floating DNA was treated with sodium bisulfite and analyzed by methylation-specific polymerase chain reaction (MSP) with primers specific for methylated or unmethylated promoter CpG island sequences of the ALX4 gene.
Results: Methylation of the ALX4 gene promoter was present in the serum DNA of patients with adenoma and colorectal cancer. A sensitivity of 68% and specificity of 88% were achieved in the detection of promoter methylation in colorectal neoplasia samples. The difference in methylation status of the ALX4 promoter between the patients with colorectal neoplasia and the control group was statistically highly significant (P < 0.001).
Conclusions: The results indicate that this serum free DNA test of methylation of the ALX4 gene promoter is a sensitive and specific method. Therefore in combination with other useful markers it seems ALX4 has the potential of a clinically useful test for the early detection of colorectal cancer.

Keywords

1.
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics. CA A Cancer J Clin 2005;55:10-30.  Back to cited text no. 1
    
2.
Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA: A Cancer J Clin 1999;49:33-64.  Back to cited text no. 2
    
3.
Malekzadeh R, Bishehsari F, Mahdavinia M, Ansari R. Epidemiology and Molecular genetics of colorectal cancer in Iran. Arch Iranian Med 2009;12:161-9.  Back to cited text no. 3
    
4.
Semnani S, Sadjadi A, Fahimi S, Nouraie M, Naeimi M, et al. Declining incidence of esophageal cancer in the Turkmen Plain, eastern part of the Caspian Littoral of Iran: A retrospective cancer surveillance. Cancer Detect Prev 2006;30:14-9.  Back to cited text no. 4
    
5.
Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009;20:556-63.  Back to cited text no. 5
    
6.
Sadjadi A, Nouraie M, Mohagheghi MA, Mousavi-Jarrahi A, Malekezadeh R, Parkin DM. Cancer occurrence in Iran in 2002: An international perspective. Asian Pac J Cancer Prev 2005;6:359-63.  Back to cited text no. 6
    
7.
Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-7.  Back to cited text no. 7
    
8.
Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. The National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopy, polypectomy. N Engl J Med 1993;329:1977-81.  Back to cited text no. 8
    
9.
He Q, Chen HY, Bai EQ, Luo YX, Fu RJ, He YS, et al. Development of multiplex Methy Light assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet Cytogenet 2010;202:1-10.  Back to cited text no. 9
    
10.
de Haan MC, Halligan S, Stoker J. Does CT colonography have a role for population-based colorectal cancer screening? Eur Radiol 2012;22:1495-503.  Back to cited text no. 10
    
11.
Fisher JA, Fikry C, Troxel AB. Cutting cost and increasing access to colorectal cancer screening: Another approach to following the guidelines. Cancer Epidemiol Biomarkers Prev 2006;15:108-13.  Back to cited text no. 11
    
12.
Levin B, Lieberman DA, McFarland B. Screening and surveillance for the early detection of CRC and adenomatous polyps. Gastroenterology 2008;135:710.  Back to cited text no. 12
    
13.
Davis KC, Cogswell ME, Rothenberg SL, Koplan JP. Lipid screening in a managed care population. Public Health Rep 1998;113:346-50.  Back to cited text no. 13
    
14.
Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: Results from the prostate cancer prevention trial. J Natl Cancer Inst 2006;98:529-34.  Back to cited text no. 14
    
15.
Regueiro CR. AGA Future Trends Committee report: Colorectal cancer: A qualitative review of emerging screening and diagnostic technologies. Gastroenterology 2005;129:1083-103.  Back to cited text no. 15
    
16.
Tänzer M, Balluff B, Distler J, Hale K, Leodolter A, Röcken C, et al. Performance of Epigenetic Markers SEPT9 and ALX4 in Plasma for Detection Colorectal Precancerous Lesions. PLoS One 2010;5:e9061.  Back to cited text no. 16
    
17.
Zou H, Harrington JJ, Shire AM, Rego RL, Wang L, Campbell ME, et al. Highly methylated genes in colorectal neoplasia: Implications for screening. Cancer Epidemiol Biomarkers Prev 2007;16:2686-96.  Back to cited text no. 17
    
18.
Ebert MP, Model F, Mooney S, Hale K, Lograsso J, Tonnes-Priddy L, et al. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology 2006;131:1418-30.  Back to cited text no. 18
    
19.
Kim MS, Lee J, Sidransky D. DNA methylation Markers in colorectal cancer. Cancer Metastasis Rev 2010;29.181-206.  Back to cited text no. 19
    
20.
deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009;55:1337-46.  Back to cited text no. 20
    
21.
Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, et al. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. Gastroentrology 2008;14:3074-80.  Back to cited text no. 21
    
22.
Antonopoulou I, Mavrogiannis LA, Wilkie AO, Morriss-Kay GM. Alx4 and Msx2 play phenotypically similar and additive roles in skull vault differentiation. J Anat 2004;204:487-99.  Back to cited text no. 22
    
23.
Mavrogiannis LA, Antonopoulou I, Baxová A, Kutílek S, Kim CA, Sugayama SM, et al. Haploin sufficiency of the human homeobox gene ALX4 causes skull ossification defects. Nat Genet 2001;27:17-8.  Back to cited text no. 23
    
24.
de Wijkerslooth TR, Bossuyt PM, Dekker E. Strategies in screening for colon carcinoma. Neth J Med 2011;69:112-9.  Back to cited text no. 24
    
25.
Brenner H, Chang-Claude J, Seiler CM, Sturmer T, Hoffmeister M. Does a negative screening colonoscopy ever need to be repeated? Gut 2006;55:1145-50.  Back to cited text no. 25
    
26.
Kim DH, Pooler BD, Weiss JM, Pickhardt PJ. Five year colorectal cancer outcomes in a large negative CT colonography screening cohort. Eur Radiol 2012;22:1488-94.  Back to cited text no. 26
    
27.
Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14.  Back to cited text no. 27
    
28.
Cheng TI, Wong JM, Hong CF, Cheng SH, Cheng TJ, Shieh MJ, et al. Colorectal cancer screening in asymptomatic adults: Comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. J Formos Med Assoc 2002;101:685-90.  Back to cited text no. 28
    
29.
Graser A, Stieber P, Nagel D, Schäfer C, Horst D, Becker CR, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 2009;58:241-8.  Back to cited text no. 29
    
30.
Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-8.  Back to cited text no. 30
    
31.
Nakama H, Yamamoto M, Kamijo N, Li T, Wei N, Fattah AS, et al. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1999;46:228-31.  Back to cited text no. 31
    
32.
Available from: http://www.gezondheidsraad.nl/nl/adviezen/bevolkings onderzoeknaar- darmkanker [Last accessed on 2012 Jan 05]  Back to cited text no. 32
    
33.
van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: A systematic review. Am J Gastroenterol 2006;101:343-50.  Back to cited text no. 33
    
34.
Pickhardt PJ, Choi JR, Hwang I, Butler JA, Puckett ML, Hildebrandt HA, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003;349:2191-200.  Back to cited text no. 34
    
35.
Daraei A, Salehi R, Salehi M, Emami MH, Jonghorbani M, Mohamadhashem F, et al. Effect of rs6983267 polymorphism in the 8q24 region and rs4444903 polymorphism in EGF gene on the risk of sporadiccolorectal cancer in Iranian population. Med Oncol 2011.  Back to cited text no. 35
    
36.
Daraei A, Salehi R, Mohamadhashem F. DNA-methyltransferase 3B 39179 G>T polymorphism and risk of sporadic colorectal cancer in a subset of Iranian population. J Res Med Sci 2011;16:807-13.  Back to cited text no. 36
[PUBMED]  Medknow Journal  
37.
Daraei A, Salehi R, Mohamadhashem F. PTGS2 (COX2) -765G>C gene polymorphism and risk of sporadic colorectal cancer in Iranian population. Mol Biol Rep 2012;39:5219-24.  Back to cited text no. 37
Advanced Biomedical Research
Volume 2015, November
November 2015
Pages 1-4